[HTML][HTML] Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, W Cheng, Y Wu, M Liu, R Liu… - BMC Pulmonary …, 2021 - Springer
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
[HTML][HTML] Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, W Cheng, Y Wu, M Liu… - BMC Pulmonary …, 2021 - ncbi.nlm.nih.gov
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, W Cheng, Y Wu… - BMC pulmonary …, 2021 - pubmed.ncbi.nlm.nih.gov
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
[引用][C] Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
S Liyuan, W Xianhui, C Wang, W Yi, L Min… - BMC Pulmonary …, 2021 - jglobal.jst.go.jp
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small
cell lung cancer identified by bioinformatics assessment | Article Information | J-GLOBAL Art …
cell lung cancer identified by bioinformatics assessment | Article Information | J-GLOBAL Art …
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
L Song, X Wang, W Cheng, Y Wu, M Liu, R Liu… - BMC Pulmonary …, 2021 - go.gale.com
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
L Song, X Wang, W Cheng, Y Wu… - BMC Pulmonary …, 2021 - search.ebscohost.com
Background: In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, C Wang, Y Wu, M Liu… - BMC Pulmonary …, 2021 - search.proquest.com
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
[HTML][HTML] Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, W Cheng… - BMC …, 2021 - bmcpulmmed.biomedcentral.com
In recent years, immunotherapies and targeted therapies contribute to population-level
improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options …
improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options …
Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
L Song, X Wang, W Cheng, Y Wu, M Liu… - BMC Pulmonary …, 2021 - europepmc.org
Background In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
[PDF][PDF] Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
L Song, X Wang, W Cheng, Y Wu, M Liu, R Liu… - 2021 - bmcpulmmed.biomedcentral.com
Background: In recent years, immunotherapies and targeted therapies contribute to
population-level improvement in NSCLC cancer-specific survival, however, the two novel …
population-level improvement in NSCLC cancer-specific survival, however, the two novel …